Commonwealth Coat of Arms of Australia

National Health (Minimum Stockholding) Determination 2023

PB 65 of 2023

made under subsection 99AEKC(2) of the

National Health Act 1953

Compilation No. 13

Compilation date: 1 October 2024

Includes amendments: F2024L00502, F2024L00809 and F2024L01234

About this compilation

This compilation

This is a compilation of the National Health (Minimum Stockholding) Determination 2023 that shows the text of the law as amended and in force on 1 October 2024 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

 

 

 

Contents

Part 1—Preliminary

1 Name

3 Authority

4 Definitions

5 Usual PBS demand

Part 2—Minimum stockholding requirement

6 Applicable quantity of a brand of a pharmaceutical item

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Endnotes

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

 

Part 1—Preliminary

 

1  Name

 (1) This instrument is the National Health (Minimum Stockholding) Determination 2023.

 (2) This instrument may also be cited as PB 65 of 2023.

3  Authority

  This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.

4  Definitions

  In this instrument:

Act means the National Health Act 1953.

brand has the same meaning as in Part VII of the Act.

data collection period has the same meaning as in the National Health (Pharmaceutical Benefits) Regulations 2017.

pharmaceutical benefit has the same meaning as in Part VII of the Act.

pharmaceutical item has the same meaning as in Part VII of the Act.

pricing quantity has the same meaning as in Part VII of the Act.

usual demand, when used in relation to a brand of a pharmaceutical item, means the usual demand for the brand of the pharmaceutical item within the meaning of section 99AEKC of the Act.

usual PBS demand, when used in relation to a brand of a pharmaceutical item, means the usual PBS demand for the brand of the pharmaceutical item ascertained in accordance with section 5.

5  Usual PBS demand

 (1) The usual PBS demand for a brand of a pharmaceutical item for a month in a data collection period for that brand is the number of packs of the brand supplied during the data collection period (the reference period) before the previous data collection period for the brand divided by the number of months in the reference period.

 (2) For the purposes of subsection (1) the number of packs of the brand supplied during a data collection period is taken to be:

 (a) the number of packs of the brand supplied as pharmaceutical benefits during that period; and

 (b) adjusted as if the size of the pack equals the pricing quantity of the brand.

 (3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

Part 2—Minimum stockholding requirement

 

6  Applicable quantity of a brand of a pharmaceutical item

  For the purposes of subparagraphs 99AEKC(1)(a)(ii) and (1)(b)(ii) of the Act, if a brand of a pharmaceutical item is specified in an item of column 4 of the table in Schedule 1 to this instrument, the quantity ascertained in accordance with column 5 of that item is the applicable quantity of the brand of the pharmaceutical item.

Schedule 1—Applicable quantity of a brand of a pharmaceutical item

Note: See section 6.

 

 

Applicable quantity of a brand of a pharmaceutical item

Column 1
Drug

Column 2
Form

Column 3
Manner of administration

Column 4
Brand

Column 5
Applicable quantity

Abacavir with lamivudine

Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg

Oral

Abacavir/Lamivudine Viatris

after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viatris and Abacavir/Lamivudine Mylan added together

Acamprosate

Tablet (enteric coated) containing acamprosate calcium 333 mg

Oral

Acamprosate Viatris

after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viatris and Acamprosate Mylan added together

Acarbose

Tablet 100 mg

Oral

GLYBOSAY

2 months stock by reference to usual demand

Acarbose

Tablet 50 mg

Oral

Acarbose Viatris

after 30 July 2024—4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together

Acarbose

Tablet 50 mg

Oral

GLYBOSAY

2 months stock by reference to usual demand

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

Fosamax Plus 70 mg/140 mcg

between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol

Oral

Fosamax Plus

between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand

Allopurinol

Tablet 100 mg

Oral

Allosig

3 months stock by reference to usual demand

Allopurinol

Tablet 100 mg

Oral

Zyloprim

3 months stock by reference to usual demand

Allopurinol

Tablet 300 mg

Oral

Zyloprim

4 months stock by reference to usual demand

Amino acid formula with vitamins and minerals without lysine and low in tryptophan

Sachets containing oral powder 24 g, 30 (GA gel)

Oral

GA gel

0 months stock by reference to usual PBS demand

Amino acid formula with vitamins and minerals without phenylalanine

Oral gel 85 g, 30 (PKU squeezie)

Oral

PKU squeezie

0 months stock by reference to usual PBS demand

Amiodarone

Tablet containing amiodarone hydrochloride 200 mg

Oral

APO-Amiodarone

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Amisulpride

Oral solution 100 mg per mL, 60 mL

Oral

Solian Solution

4 months stock by reference to usual PBS demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 10 mg

Oral

APO-Amitriptyline 10

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 10 mg

Oral

ENTRIP

4 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 25 mg

Oral

APO-Amitriptyline 25

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 25 mg

Oral

APX‑Amitriptyline

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—5 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 25 mg

Oral

ENTRIP

4 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 50 mg

Oral

APO-Amitriptyline 50

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 50 mg

Oral

APX‑Amitriptyline

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—4.5 months stock by reference to usual demand

Amitriptyline

Tablet containing amitriptyline hydrochloride 50 mg

Oral

ENTRIP

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—4.5 months stock by reference to usual demand

Amoxicillin

Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL

Oral

Amoxil

4 months stock by reference to usual PBS demand

Amoxicillin with clavulanic acid

Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

Oral

AlphaClav Duo Forte Viatris

6 months stock by reference to usual demand

Amphotericin B

Lozenge 10 mg

Oral

Fungilin

4 months stock by reference to usual PBS demand

Anakinra

Injection 100 mg in 0.67 mL single use pre‑filled syringe

Injection

Kineret

6 months stock by reference to usual PBS demand

Aripiprazole

Tablet 10 mg

Oral

APO‑Aripiprazole

3 months stock by reference to usual demand

Aripiprazole

Tablet 15 mg

Oral

APO‑Aripiprazole

3 months stock by reference to usual demand

Aripiprazole

Tablet 15 mg

Oral

Aripic Aripiprazole

between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand

Aripiprazole

Tablet 20 mg

Oral

APO‑Aripiprazole

3 months stock by reference to usual demand

Aripiprazole

Tablet 20 mg

Oral

Aripic Aripiprazole

between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand

Aripiprazole

Tablet 30 mg

Oral

APO‑Aripiprazole

3 months stock by reference to usual demand

Aripiprazole

Tablet 30 mg

Oral

Aripic Aripiprazole

between 1 October 2024 and 31 March 2025—0 months stock by reference to usual demand

Atenolol

Oral solution 50 mg in 10 mL, 300 mL

Oral

Atenolol‑AFT

4 months stock by reference to usual PBS demand

Atenolol

Tablet 50 mg

Oral

APO-Atenolol

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Atenolol

Tablet 50 mg

Oral

APX‑Atenolol

4 months stock by reference to usual demand

Atenolol

Tablet 50 mg

Oral

Tensig

4 months stock by reference to usual demand

Atomoxetine

Capsule 10 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 100 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 18 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 25 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 40 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 60 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Atomoxetine

Capsule 80 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

Azithromycin

Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL

Oral

Zithromax

4 months stock by reference to usual PBS demand

Azithromycin

Tablet 500 mg (as dihydrate)

Oral

Azithromycin Viatris

after 30 September 2024—4 months stock by reference to usual demand of both Azithromycin Viatris and Azithromycin Mylan added together

Baclofen

Tablet 10 mg

Oral

APO‑Baclofen

3 months stock by reference to usual demand

Benzathine benzylpenicillin

Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre‑filled syringe

Injection

Bicillin L‑A

6 months stock by reference to usual PBS demand

Benzathine benzylpenicillin

Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre‑filled syringe

Injection

Bicillin L‑A

6 months stock by reference to usual PBS demand

Bisacodyl

Tablet 5 mg

Oral

Lax-Tab

between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand

Bisoprolol

Tablet containing bisoprolol fumarate 10 mg

Oral

Cipla Bisoprolol

between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

Bisoprolol

Tablet containing bisoprolol fumarate 2.5 mg

Oral

Cipla Bisoprolol

between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

Bisoprolol

Tablet containing bisoprolol fumarate 5 mg

Oral

Cipla Bisoprolol

between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

Bosentan

Tablet 125 mg (as monohydrate)

Oral

Bosentan APO

3 months stock by reference to usual demand

Bosentan

Tablet 125 mg (as monohydrate)

Oral

BOSLEER

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Bosentan

Tablet 62.5 mg (as monohydrate)

Oral

BOSLEER

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Bosentan

Tablet 62.5 mg (as monohydrate)

Oral

Tracleer

between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand

Budesonide

Nebuliser suspension 500 micrograms in 2 mL single dose units, 30

Inhalation

Pulmicort Respules

6 months stock by reference to usual PBS demand

Budesonide

Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses

Inhalation by Mouth

Pulmicort Turbuhaler

6 months stock by reference to usual PBS demand

Calcitriol

Capsule 0.25 microgram

Oral

APO-Calcitriol

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Calcitriol

Capsule 0.25 microgram

Oral

Kosteo

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Calcium

Tablet, chewable, 500 mg (as carbonate)

Oral

Cal‑500

6 months stock by reference to usual PBS demand

Captopril

Oral solution 5 mg per mL, 95 mL

Oral

Capoten

4 months stock by reference to usual PBS demand

Carmellose

Eye drops containing carmellose sodium 10 mg per mL, 15 mL

Application to the Eye

Refresh Liquigel

between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand

Carmellose

Eye drops containing carmellose sodium 5 mg per mL, 15 mL

Application to the Eye

Refresh Tears Plus

between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand

Carmellose with glycerin

Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL

Application to the Eye

Optive

between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand

Cefazolin

Powder for injection 2 g (as sodium)

Injection

Cephazolin Viatris

after 30 July 2024—6 months stock by reference to usual demand of both Cephazolin Viatris and Cephazolin Alphapharm added together

Cefepime

Powder for injection 1 g (as hydrochloride)

Injection

Cefepime Kabi

between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

Cefepime

Powder for injection 2 g (as hydrochloride)

Injection

Cefepime Kabi

between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

Ceftriaxone

Powder for injection 1 g (as sodium)

Injection

Ceftriaxone Viatris

after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone  Alphapharm added together

Ceftriaxone

Powder for injection 2 g (as sodium)

Injection

Ceftriaxone Viatris

after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together

Chloramphenicol

Eye drops 5 mg per mL, 10 mL

Application to the Eye

Chlorsig

4 months stock by reference to usual PBS demand

Chlorpromazine

Injection containing chlorpromazine hydrochloride 50 mg in 2 mL

Injection

Largactil

6 months stock by reference to usual PBS demand

Chlorpromazine

Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL

Oral

Largactil

6 months stock by reference to usual PBS demand

Chlorpromazine

Tablet containing chlorpromazine hydrochloride 100 mg

Oral

Largactil

6 months stock by reference to usual PBS demand

Chlorpromazine

Tablet containing chlorpromazine hydrochloride 25 mg

Oral

Largactil

6 months stock by reference to usual PBS demand

Chlortalidone

Tablet 25 mg

Oral

Hygroton 25

4 months stock by reference to usual PBS demand

Ciclosporin

Capsule 10 mg

Oral

Neoral 10

4 months stock by reference to usual PBS demand

Ciclosporin

Capsule 100 mg

Oral

APO‑Ciclosporin

2.5 months stock by reference to usual demand

Ciclosporin

Capsule 25 mg

Oral

APO‑Ciclosporin

3 months stock by reference to usual demand

Ciclosporin

Capsule 50 mg

Oral

APO‑Ciclosporin

3 months stock by reference to usual demand

Ciclosporin

Oral liquid 100 mg per mL, 50 mL

Oral

Neoral

4 months stock by reference to usual PBS demand

Ciprofloxacin

Tablet 250 mg (as hydrochloride)

Oral

APX-Ciprofloxacin

between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

Ciprofloxacin

Tablet 500 mg (as hydrochloride)

Oral

APX-Ciprofloxacin

between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

Ciprofloxacin

Tablet 750 mg (as hydrochloride)

Oral

APX-Ciprofloxacin

between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

Clarithromycin

Powder for oral liquid 250 mg per 5 mL, 50 mL

Oral

Klacid

4 months stock by reference to usual PBS demand

Clonazepam

Oral liquid 2.5 mg per mL, 10 mL

Oral

Rivotril

6 months stock by reference to usual PBS demand

Codeine

Tablet containing codeine phosphate hemihydrate 30 mg

Oral

Aspen Pharma Pty Ltd

4 months stock by reference to usual PBS demand

Dantrolene

Capsule containing dantrolene sodium hemiheptahydrate 25 mg

Oral

Dantrium

6 months stock by reference to usual PBS demand

Diazepam

Oral liquid 10 mg per 10 mL, 100 mL

Oral

Diazepam Elixir

4 months stock by reference to usual PBS demand

Diazepam

Tablet 2 mg

Oral

APO-Diazepam

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Diazepam

Tablet 5 mg

Oral

APO-Diazepam

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

Oral

APO-Diclofenac

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 50 mg

Oral

APO-Diclofenac

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Diphtheria and tetanus vaccine, adsorbed, diluted for adult use

Injection 0.5 mL in pre‑filled syringe

Injection

ADT Booster

6 months stock by reference to usual PBS demand

Dolutegravir with abacavir and lamivudine

Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg

Oral

Triumeq

6 months stock by reference to usual PBS demand

Dosulepin

Capsule containing dosulepin hydrochloride 25 mg

Oral

Dosulepin Viatris

after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together

Doxorubicin ‑ pegylated liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL

Injection

Liposomal Doxorubicin SUN

3 months stock by reference to usual demand

Doxorubicin ‑ pegylated liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL

Injection

Liposomal Doxorubicin SUN

3 months stock by reference to usual demand

Doxycycline

Tablet 100 mg (as hyclate)

Oral

APX‑Doxycycline

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Doxycycline

Tablet 50 mg (as hyclate)

Oral

Doxsig

4 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 10 mg

Oral

APO‑Enalapril

4 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 10 mg

Oral

Malean

4 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 20 mg

Oral

APO‑Enalapril

3 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 20 mg

Oral

Malean

3 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 5 mg

Oral

Acetec

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—2 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 5 mg

Oral

APO‑Enalapril

4 months stock by reference to usual demand

Enalapril

Tablet containing enalapril maleate 5 mg

Oral

Malean

4 months stock by reference to usual demand

Entecavir

Tablet 0.5 mg (as monohydrate)

Oral

Entecavir Viatris

after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together

Entecavir

Tablet 0.5 mg (as monohydrate)

Oral

ENTECLUDE

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Entecavir

Tablet 1 mg (as monohydrate)

Oral

ENTECLUDE

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Epoprostenol

Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL

Injection

Flolan

between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

Epoprostenol

Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL

Injection

Flolan

between 1 October 2024 and 30 November 2024—0 months stock by reference to usual demand

Escitalopram

Oral solution 20 mg (as oxalate) per mL, 15 mL

Oral

Lexapro

4 months stock by reference to usual PBS demand

Escitalopram

Tablet 10 mg (as oxalate)

Oral

APX‑Escitalopram

4 months stock by reference to usual demand

Escitalopram

Tablet 20 mg (as oxalate)

Oral

APX‑Escitalopram

4 months stock by reference to usual demand

Esomeprazole

Tablet (enteric coated) 20 mg (as magnesium trihydrate)

Oral

Esomeprazole Viatris

after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together

Esomeprazole

Tablet (enteric coated) 40 mg (as magnesium trihydrate)

Oral

Esomeprazole Viatris

after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together

Ezetimibe with simvastatin

Tablet 10 mg‑10 mg

Oral

APO‑Ezetimibe/Simvastatin 10/10

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑10 mg

Oral

EZETORIN

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑20 mg

Oral

APO‑Ezetimibe/Simvastatin 10/20

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑20 mg

Oral

EZETORIN

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑40 mg

Oral

APO‑Ezetimibe/Simvastatin 10/40

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑40 mg

Oral

EZETORIN

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑80 mg

Oral

APO‑Ezetimibe/Simvastatin 10/80

3 months stock by reference to usual demand

Ezetimibe with simvastatin

Tablet 10 mg‑80 mg

Oral

EZETORIN

3 months stock by reference to usual demand

Felodipine

Tablet 2.5 mg (extended release)

Oral

Felodur ER 2.5 mg

2.5 months stock by reference to usual demand

Felodipine

Tablet 2.5 mg (extended release)

Oral

Plendil ER

2.5 months stock by reference to usual demand

Fentanyl

Transdermal patch 10.20 mg

Transdermal

Denpax

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—2.5 months stock by reference to usual demand

Fentanyl

Transdermal patch 12.6 mg

Transdermal

APO‑Fentanyl

3 months stock by reference to usual demand

Fentanyl

Transdermal patch 16.8 mg

Transdermal

APO‑Fentanyl

3 months stock by reference to usual demand

Fentanyl

Transdermal patch 2.1 mg

Transdermal

APO‑Fentanyl

(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

(b) after 31 December 2023—3.5 months stock by reference to usual demand

Fentanyl

Transdermal patch 4.2 mg

Transdermal

APO‑Fentanyl

3 months stock by reference to usual demand

Fentanyl

Transdermal patch 5.10 mg

Transdermal

Denpax

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—2.5 months stock by reference to usual demand

Fentanyl

Transdermal patch 8.4 mg

Transdermal

APO‑Fentanyl

3 months stock by reference to usual demand

Fluconazole

Powder for oral suspension 50 mg in 5 mL, 35 mL

Oral

Diflucan

4 months stock by reference to usual PBS demand

Folic acid

Tablet 5 mg

Oral

Megafol 5

4 months stock by reference to usual PBS demand

Folic acid

Tablet 500 micrograms

Oral

Foltabs 500

4 months stock by reference to usual PBS demand

Folic acid

Tablet 500 micrograms

Oral

Megafol 0.5

4 months stock by reference to usual PBS demand

Fosinopril

Tablet containing fosinopril sodium 10 mg

Oral

APO‑Fosinopril

3 months stock by reference to usual demand

Fosinopril

Tablet containing fosinopril sodium 20 mg

Oral

APO‑Fosinopril

3 months stock by reference to usual demand

Framycetin

Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL

Application to the Eye/Ear

Soframycin

4 months stock by reference to usual PBS demand

Furosemide

Oral solution 10 mg per mL, 30 mL

Oral

Lasix

4 months stock by reference to usual PBS demand

Fusidic acid

Tablet containing sodium fusidate 250 mg

Oral

Fucidin

6 months stock by reference to usual PBS demand

Gabapentin

Capsule 400 mg

Oral

GAPENTIN

3 months stock by reference to usual demand

Galantamine

Capsule (prolonged release) 16 mg (as hydrobromide)

Oral

Gamine XR

3 months stock by reference to usual demand

Galantamine

Capsule (prolonged release) 24 mg (as hydrobromide)

Oral

Gamine XR

3 months stock by reference to usual demand

Galantamine

Capsule (prolonged release) 8 mg (as hydrobromide)

Oral

Galantyl

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—1.5 months stock by reference to usual demand

Galantamine

Capsule (prolonged release) 8 mg (as hydrobromide)

Oral

Gamine XR

3 months stock by reference to usual demand

Glucose and ketone indicator‑urine

Test strips, 50 (Keto‑Diastix)

For External Use

Keto‑Diastix

4 months stock by reference to usual PBS demand

Haloperidol

Tablet 1.5 mg

Oral

Serenace

4 months stock by reference to usual PBS demand

Haloperidol

Tablet 5 mg

Oral

Serenace

4 months stock by reference to usual PBS demand

Haloperidol

Tablet 500 micrograms

Oral

Serenace

4 months stock by reference to usual PBS demand

Heparin

Injection 5,000 units (as sodium) in 0.2 ml

Injection

DBL Heparin Sodium

6 months stock by reference to usual PBS demand

Hypromellose

Eye drops 3 mg per mL, 10 mL

Application to the Eye

Genteal

between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

Hypromellose

Eye drops 3 mg per mL, 10 mL

Application to the Eye

In a Wink Moisturising

between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

Hypromellose with carbomer 980

Ocular lubricating gel 3 mg-2 mg per g, 10 g

Application to the Eye

Genteal gel

between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand

Hypromellose with carbomer 980

Ocular lubricating gel 3 mg-2 mg per g, 10 g

Application to the Eye

HPMC PAA

between 1 October 2024 and 30 June 2025—0 months stock by reference to usual demand

Ibuprofen

Tablet 400 mg

Oral

MEDICHOICE IBUPROFEN 400 mg

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Imatinib

Capsule 100 mg (as mesilate)

Oral

Imatinib‑APOTEX

3 months stock by reference to usual demand

Imatinib

Capsule 400 mg (as mesilate)

Oral

Imatinib‑APOTEX

3 months stock by reference to usual demand

Indapamide

Tablet containing indapamide hemihydrate 2.5 mg

Oral

Insig

3 months stock by reference to usual demand

Insect allergen extract‑honey bee venom

Injection set containing 550 micrograms with diluent

Injection

Hymenoptera Honey Bee Venom

6 months stock by reference to usual PBS demand

Insect allergen extract‑paper wasp venom

Injection set containing 550 micrograms with diluent

Injection

Hymenoptera Paper Wasp Venom

6 months stock by reference to usual PBS demand

Insect allergen extract‑yellow jacket venom

Injection set containing 550 micrograms with diluent

Injection

Hymenoptera Yellow Jacket Venom

6 months stock by reference to usual PBS demand

Irbesartan

Tablet 75 mg

Oral

Karvea

between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

Irbesartan with hydrochlorothiazide

Tablet 150 mg‑12.5 mg

Oral

AVSARTAN HCT 150/12.5

4 months stock by reference to usual demand

Isoleucine with carbohydrate

Sachets of oral powder 4 g containing 1 g isoleucine, 30 (Isoleucine 1000)

Oral

Isoleucine 1000

0 months stock by reference to usual PBS demand

Isoleucine with carbohydrate

Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)

Oral

Isoleucine 50

0 months stock by reference to usual PBS demand

Itraconazole

Capsule 100 mg

Oral

APO-Itraconazole

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Labetalol

Tablet containing labetalol hydrochloride 100 mg

Oral

Presolol 100

between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand

Lansoprazole

Tablet 15 mg (orally disintegrating)

Oral

APO‑Lansoprazole ODT

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—4.5 months stock by reference to usual demand

Lansoprazole

Tablet 30 mg (orally disintegrating)

Oral

APO‑Lansoprazole ODT

3 months stock by reference to usual demand

Latanoprost

Eye drops 50 micrograms per mL, 2.5 mL

Application to the Eye

APO‑Latanoprost

2 months stock by reference to usual demand

Latanoprost with timolol

Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL

Application to the Eye

APO‑Latanoprost/Timolol 0.05/5

2.5 months stock by reference to usual demand

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

APO-Levetiracetam

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Keppra

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Kerron

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Levetiracetam GH

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Oral solution 100 mg per mL, 300 mL

Oral

Levetiracetam-AFT

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

APO-Levetiracetam

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Keppra

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Kevtam 1000

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levactam

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levetiracetam GH

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levetiracetam Mylan

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levetiracetam SZ

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levetiracetam Viatris

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

Levi 1000

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam

Tablet 1 g

Oral

NOUMED LEVETIRACETAM

between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Lithium

Tablet containing lithium carbonate 250 mg

Oral

Lithicarb

6 months stock by reference to usual PBS demand

Lithium

Tablet containing lithium carbonate 450 mg (slow release)

Oral

Quilonum SR

6 months stock by reference to usual PBS demand

Macrogol 3350

Sachets containing powder for oral solution 13.125 g with electrolytes, 30

Oral

Movicol

between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand

Meloxicam

Tablet 7.5 mg

Oral

MELOBIC

4 months stock by reference to usual demand

Methoxyflurane

Liquid for inhalation 999 mg per g, 3 ml (with inhaler)

Inhalation by mouth

Penthrox

6 months stock by reference to usual PBS demand

Metoprolol

Tablet containing metoprolol tartrate 100 mg

Oral

Metrol 100

4 months stock by reference to usual demand

Metronidazole

Suppositories 500 mg, 10

Rectal

Flagyl

6 months stock by reference to usual PBS demand

Milk protein and fat formula with vitamins and minerals ‑‑ carbohydrate free

Oral powder 225 g (Carbohydrate Free Mixture)

Oral

Carbohydrate Free Mixture

6 months stock by reference to usual PBS demand

Modafinil

Tablet 100 mg

Oral

Modafin

3 months stock by reference to usual demand

Nevirapine

Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL

Oral

Viramune

4 months stock by reference to usual PBS demand

Nevirapine

Tablet 200 mg

Oral

Nevirapine Viatris

after 30 November 2024— 4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together

Nevirapine

Tablet 400 mg (extended release)

Oral

Viramune XR

between 1 October 2024 and 30 September 2025—0 months stock by reference to usual demand

Nicorandil

Tablets 10 mg, 60

Oral

APO‑Nicorandil

2 months stock by reference to usual demand

Nicorandil

Tablets 10 mg, 60

Oral

Ikotab

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—2 months stock by reference to usual demand

Nicorandil

Tablets 20 mg, 60

Oral

APO‑Nicorandil

2 months stock by reference to usual demand

Nicorandil

Tablets 20 mg, 60

Oral

Ikotab

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—2 months stock by reference to usual demand

Nifedipine

Tablet 30 mg (controlled release)

Oral

Addos XR 30

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Nifedipine

Tablet 60 mg (controlled release)

Oral

Addos XR 60

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Norfloxacin

Tablet 400 mg

Oral

APO‑Norfloxacin

2.5 months stock by reference to usual demand

Nortriptyline

Tablet 10 mg (as hydrochloride)

Oral

NortriTABS 10 mg

between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand

Nortriptyline

Tablet 25 mg (as hydrochloride)

Oral

NortriTABS 25 mg

between 1 October 2024 and 31 December 2024—0 months stock by reference to usual demand

Olanzapine

Tablet 10 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together

Olanzapine

Tablet 15 mg (orally disintegrating)

Oral

PRYZEX ODT

(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

(b) after 31 December 2023—3.5 months stock by reference to usual demand

Olanzapine

Tablet 15 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.

Olanzapine

Tablet 20 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together

Olanzapine

Tablet 5 mg (orally disintegrating)

Oral

APO‑Olanzapine ODT

3 months stock by reference to usual demand

Olanzapine

Tablet 5 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together

Olmesartan

Tablet containing olmesartan medoxomil 20 mg

Oral

OLMERTAN

3 months stock by reference to usual demand

Olmesartan

Tablet containing olmesartan medoxomil 40 mg

Oral

OLMERTAN

(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

(b) after 31 December 2023—3.5 months stock by reference to usual demand

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

Oral

OLMERTAN COMBI 20/12.5

3 months stock by reference to usual demand

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

Oral

OLMERTAN COMBI 40/12.5

3 months stock by reference to usual demand

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

Oral

OLMERTAN COMBI 40/25

3 months stock by reference to usual demand

Ondansetron

Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL

Oral

Zofran syrup 50 mL

4 months stock by reference to usual PBS demand

Oxazepam

Tablet 30 mg

Oral

APO‑Oxazepam

5.5 months stock by reference to usual demand

Oxazepam

Tablet 30 mg

Oral

Murelax

5 months stock by reference to usual demand

Oxycodone

Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL

Oral

OxyNorm Liquid 1mg/mL

4 months stock by reference to usual PBS demand

Oxycodone

Tablet containing oxycodone hydrochloride 5 mg

Oral

Oxycodone Viatris

after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together

Pantoprazole

Sachet containing granules 40 mg (as sodium sesquihydrate)

Oral

Somac

4 months stock by reference to usual PBS demand

Pantoprazole

Tablet (enteric coated) 20 mg (as sodium sesquihydrate)

Oral

APO‑Pantoprazole

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Pantoprazole

Tablet (enteric coated) 40 mg (as sodium sesquihydrate)

Oral

Sozol

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Periciazine

Tablet 10 mg

Oral

Neulactil

6 months stock by reference to usual PBS demand

Periciazine

Tablet 2.5 mg

Oral

Neulactil

6 months stock by reference to usual PBS demand

Perindopril

Tablet containing perindopril erbumine 2 mg

Oral

Indosyl Mono 2

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—5 months stock by reference to usual demand

Perindopril

Tablet containing perindopril erbumine 4 mg

Oral

Indosyl Mono 4

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Perindopril with indapamide

Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg

Oral

Indosyl Combi 4/1.25

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—5 months stock by reference to usual demand

Perindopril with indapamide

Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg

Oral

Perindo Combi 4/1.25

(a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand

(b) after 31 December 2023—2.5 months stock by reference to usual demand

Permethrin

Cream 50 mg per g, 30 g

Application

Lyclear

6 months stock by reference to usual PBS demand

Pimecrolimus

Cream 10 mg per g, 15 g

Application

Elidel

6 months stock by reference to usual PBS demand

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Acpio 15

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Acpio 30

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Acpio 45

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Pregabalin

Capsule 150 mg

Oral

Cipla Pregabalin

between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand

Probenecid

Tablet 500 mg

Oral

Pro‑Cid

6 months stock by reference to usual PBS demand

Prochlorperazine

Injection containing prochlorperazine mesilate 12.5 mg in 1 mL

Injection

Stemetil

6 months stock by reference to usual PBS demand

Promethazine

Injection containing promethazine hydrochloride 50 mg in 2 mL

Injection

DBL Promethazine Hydrochloride

6 months stock by reference to usual PBS demand

Protein hydrolysate formula with medium chain triglycerides

Oral powder 450 g (Aptamil Gold+ Pepti‑Junior)

Oral

Aptamil Gold+ Pepti‑Junior

6 months stock by reference to usual PBS demand

Quinapril

Tablet 10 mg (as hydrochloride)

Oral

APO‑Quinapril

3 months stock by reference to usual demand

Quinapril

Tablet 20 mg (as hydrochloride)

Oral

APO‑Quinapril

3 months stock by reference to usual demand

Rabeprazole

Tablet containing rabeprazole sodium 10 mg (enteric coated)

Oral

APO‑Rabeprazole

4 months stock by reference to usual demand

Rabeprazole

Tablet containing rabeprazole sodium 10 mg (enteric coated)

Oral

Parbezol

4 months stock by reference to usual demand

Raloxifene

Tablet containing raloxifene hydrochloride 60 mg

Oral

RALOVISTA

3 months stock by reference to usual demand

Ramipril

Capsule 10 mg

Oral

APX‑Ramipril

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Ramipril

Capsule 10 mg

Oral

Prilace

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

Ramipril

Tablet 1.25 mg

Oral

Prilace

2.5 months stock by reference to usual demand

Ramipril

Tablet 1.25 mg

Oral

Tryzan Tabs 1.25

(a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand

(b) after 31 December 2023—3 months stock by reference to usual demand

Ramipril with felodipine

Tablet 2.5 mg‑2.5 mg (modified release)

Oral

Triasyn 2.5/2.5

4 months stock by reference to usual PBS demand

Riluzole

Tablet 50 mg

Oral

APO-Riluzole

between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand

Risedronic acid

Tablet containing risedronate sodium 150 mg

Oral

APO‑Risedronate

3 months stock by reference to usual demand

Risperidone

Tablet 3 mg

Oral

APO‑Risperidone

(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

(b) after 31 December 2023—3.5 months stock by reference to usual demand

Risperidone

Tablet 3 mg

Oral

Rispa

3 months stock by reference to usual demand

Roxithromycin

Tablet 150 mg

Oral

APX‑Roxithromycin

4 months stock by reference to usual demand

Roxithromycin

Tablet 300 mg

Oral

APX‑Roxithromycin

(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand

(b) after 31 December 2023—5 months stock by reference to usual demand

Salbutamol

Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30

Inhalation

Salbutamol Cipla

between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.

Salbutamol

Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30

Inhalation

Salbutamol Cipla

between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand.

Sodium acid phosphate

Tablet, compound effervescent, equivalent to 500 mg phosphorus

Oral

PHOSPHATE PHEBRA

6 months stock by reference to usual PBS demand

Sotalol

Tablet containing sotalol hydrochloride 160 mg

Oral

Cardol

(a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

(b) after 31 December 2023—1.5 months stock by reference to usual demand

Sumatriptan

Tablet 50 mg (as succinate)

Oral

APO‑Sumatriptan

4 months stock by reference to usual demand

Tacrolimus

Capsule 1 mg

Oral

Tacrograf

3 months stock by reference to usual demand

Tacrolimus

Capsule 5 mg

Oral

Tacrograf

3 months stock by reference to usual demand

Temazepam

Tablet 10 mg

Oral

APO‑Temazepam

2.5 months stock by reference to usual demand

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

Oral

Tenofovir/Emtricitabine 300/200 APOTEX

3 months stock by reference to usual demand

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

Oral

Tenofovir Disoproxil Emtricitabine Viatris 300/200

after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together

Thiamine

Tablet containing thiamine hydrochloride 100 mg

Oral

Betavit

4 months stock by reference to usual PBS demand

Tobramycin

Injection 80 mg (as sulfate) in 2 mL (without preservative)

Injection

Pfizer Australia Pty Ltd

2 months stock by reference to usual demand

Tobramycin

Injection 80 mg in 2 mL

Injection

Tobramycin Viatris

4 months stock by reference to usual demand of both Tobramycin Viatris and Tobramycin Mylan added together

Topiramate

Tablet 100 mg

Oral

APO‑Topiramate

3 months stock by reference to usual demand

Topiramate

Tablet 200 mg

Oral

APO‑Topiramate

3 months stock by reference to usual demand

Topiramate

Tablet 25 mg

Oral

APO‑Topiramate

3 months stock by reference to usual demand

Topiramate

Tablet 50 mg

Oral

APO‑Topiramate

3 months stock by reference to usual demand

Tramadol

Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL

Oral

Tramal

4 months stock by reference to usual PBS demand

Trandolapril

Capsule 1 mg

Oral

Dolapril 1

3 months stock by reference to usual demand

Trandolapril

Capsule 2 mg

Oral

Dolapril 2

3 months stock by reference to usual demand

Trandolapril

Capsule 4 mg

Oral

Dolapril 4

3 months stock by reference to usual demand

Trandolapril

Capsule 500 micrograms

Oral

Dolapril 0.5

2.5 months stock by reference to usual demand

Triglycerides—medium chain, formula

Oral powder 400 g (Lipistart)

Oral

Lipistart

0 months stock by reference to usual PBS demand

Trimethoprim

Tablet 300 mg

Oral

Trimethoprim Viatris

after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together

Valaciclovir

Tablet 500 mg (as hydrochloride)

Oral

Valaciclovir generichealth

between 1 August 2024 and 31 October 2024—0 months stock by reference to usual demand

Valganciclovir

Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL

Oral

Valcyte

4 months stock by reference to usual PBS demand

Valproic acid

Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL

Oral

Epilim Liquid

6 months stock by reference to usual PBS demand

Valproic acid

Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL

Oral

Epilim Syrup

6 months stock by reference to usual PBS demand

Valproic acid

Tablet, crushable, containing sodium valproate 100 mg

Oral

Epilim

4 months stock by reference to usual PBS demand

Voriconazole

Powder for oral suspension 40 mg per mL, 70 mL

Oral

Vfend

4 months stock by reference to usual PBS demand

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

 

Endnote 2—Abbreviation key

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

/sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

National Health (Minimum Stockholding) Determination 2023 (PB 65 of 2023)

30 June 2023 (F2023L00919)

1 July 2023 (s 2(1) item 1)

 

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023 (PB 103 of 2023)

29 Sept 2023 (F2023L01338)

1 Oct 2023 (s 2(1) item 1)

—

National Health (Minimum Stockholding) Amendment Determination (No. 2) 2023 (PB 111 of 2023)

31 Oct 2023 (F2023L01455)

1 Nov 2023 (s 2(1) item 1)

—

National Health (Minimum Stockholding) Amendment Determination (No. 3) 2023 (PB 125 of 2023)

30 Nov 2023 (F2023L01573)

1 Dec 2023 (s 2(1) item 1)

—

National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023 (PB 136 of 2023)

18 Dec 2023 (F2023L01702)

Sch 2: 1 Feb 2024 (s 2(1) item 3)
Sch 3: 1 Apr 2024 (s 2(1) item 4)
Remainder: 1 Jan 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024 (PB 10 of 2024)

31 Jan 2024 (F2024L00114)

Sch 2: 1 June 2024 (s 2(1) item 3)
Remainder: 1 Feb 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024 (PB 24 of 2024)

29 Feb 2024 (F2024L00228)

1 Mar 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 3) 2024 (PB 32 of 2024)

28 Mar 2024 (F2024L00411)

1 Apr 2024 (s 2(1) items 1, 2, 3)

—

National Health (Minimum Stockholding) Amendment Determination (No.4) 2024 (PB 49 of 2024)

30 Apr 2024 (F2024L00502)

Sch 2: 1 Oct 2024 (s 2(1) item 3)
Remainder: 1 May 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 5) 2024 (PB 61 of 2024)

30 May 2024 (F2024L00591)

1 June 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024 (PB 75 of 2024)

28 June 2024 (F2024L00809)

Sch 2: 1 Oct 2024 (s 2(1) item 3)
Sch 3: 1 Dec 2024 (s 2(1) item 4)
Remainder: 1 July 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 7) 2024 (PB 83 of 2024)

31 July 2024 (F2024L00942)

1 Aug 2024 (s 2(1) items 1, 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 8) 2024 (PB 90 of 2024)

28 Aug 2024 (F2024L01065)

1 Sept 2024 (s 2(1) item 2)

—

National Health (Minimum Stockholding) Amendment Determination (No. 9) 2024 (PB 102 of 2024)

27 September 2024 (F2024L01234)

Sch 3: 1 Dec 2024 (s 2(1) item 4)
Remainder: 1 Oct 2024 (s 2(1) items 1–3)

—

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

s 2.....................

rep LA s 48D

s 5.....................

am F2023L01338

Schedule 1

 

Schedule 1................

am F2023L01338

 

rs F2023L01455

 

am F2023L01455; F2023L01573

 

ed C3

 

am F2023L01702; F2024L00114

 

ed C5

 

am F2024L00228; F2024L00411; F2024L00502; F2024L00591; F2024L00809 (Sch 3); F2024L00942

 

ed C11

 

am F2024L01065; F2024L00502 (Sch 2 item 4 md not incorp); F2024L00809; F2024L01234 (Sch 3)